600276 Jiangsu Hengrui Pharmaceuticals

Hengrui Pharmaceutical: The Silicon Valley Bank incident did not have any negative impact on the company's overseas R&D activities and other operating activities

14:07

Hengrui Pharmaceutical (600276.SH): HRS-5635, a class 1 innovative drug, was approved for clinical trials

Gelonhui, March 28, 丨 Hengrui Pharmaceutical (600276.SH) announced that recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the China Drug Administration (“China Drug Administration”) for issuing a “Drug Clinical Trial Approval Notice” for HRS-5635, which will begin clinical trials in the near future. Approval conclusion: According to the “Drug Administration Law of the People's Republic of China” and related regulations, the HRS-5635 injection received on January 9, 2023 met the relevant requirements for drug registration, and it was agreed to carry out clinical trials for chronic hepatitis B in accordance with the submitted plan. HRS-5635 is public

03-28 15:40

Hengrui Pharmaceutical: HRS-5635 injection approved drug clinical trial

03-28 15:38

Hengrui Pharmaceutical (600276.SH): Revirulamide tablets for treatment of patients with metastatic hormone-sensitive prostate cancer with a high tumor burden were approved and converted to full approval

According to the Zhitong Finance App, Hengrui Pharmaceutical (600276.SH) announced that recently, the company received approval from the China Drug Administration (“China Drug Administration”) to issue a “Drug Supplement Application Approval Notice” for leviruramide tablets. The China Drug Administration approved the use of leviruramide tablets to “treat patients with metastatic hormone-sensitive prostate cancer (MHSPC) with high tumor load” from conditional approval to routine approval. According to reports, reviverutamide tablets are second-generation AR inhibitors. Compared with first-generation AR inhibitors, they have a stronger AR inhibitory effect and have no agonizing effect. In June 2022, the company obtained leviruramide tablets

03-27 16:00

Hengrui Pharmaceutical: Obtaining Approval Notice for Revirutamide Tablet Supplement Application

03-27 15:47

Jiangsu Hengrui Pharma Unit Gets Nod to Test HRS-5965 Tablets

03:35 AM EDT, 03/24/2023 (MT Newswires) -- Chengdu Shengdi Pharmaceutical, a subsidiary of Jiangsu Hengrui Pharmaceuticals (SHA:600276), will hold clinical trials for HRS-5965 tablets after securing a

03-24 15:38

Hengrui Pharmaceutical (600276.SH) obtained approval notice for clinical trials of acripopapitanolamine tablets

According to the Zhitong Finance App, Hengrui Pharmaceutical (600276.SH) announced that the company received approval from the China Drug Administration to issue a “Drug Clinical Trial Approval Notice” for acitoppa ethanolamine tablets and agreed to carry out clinical trials of combined cyclosporine (CsA) for the initial treatment of non-severe aplastic anemia (NSAA). Hytrapopa ethanolamine tablets have been approved for marketing for two indications, namely: approved by the National Drug Administration in June 2021 for the treatment of adult patients with chronic primary immune thrombocytopenia who have not responded well to treatments such as glucocorticoids, immunoglobulins, etc., and for immunity

03-23 16:06

Hengrui Pharmaceutical (600276.SH): Subsidiary HRS-5965 tablets approved for clinical trials

Gelonhui, March 23, 丨 Hengrui Pharmaceutical (600276.SH) announced that recently, Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the China Drug Administration to issue a “Drug Clinical Trial Approval Notice” on HRS-5965, and will conduct clinical trials in the near future. According to the “Drug Administration Law of the People's Republic of China” and related regulations, HRS-5965 tablets (specifications 25 mg, 100 mg) received on December 26, 2022 met the relevant requirements for drug registration and agreed to participate in complement-mediated indications related to hemolytic anemia (including paroxysmal nocturnal hemoglobinuria and SARS)

03-23 15:45

Hengrui Pharmaceutical (600276.SH): Acitripopa ethanolamine tablets were approved to conduct clinical trials in combination with cyclosporine (CsA) for the initial treatment of non-severe aplastic anemia (NSAA)

Gelonhui, March 23, 丨 Hengrui Pharmaceutical (600276.SH) announced that recently, the company received approval from the China Drug Administration (“China Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for acitripopa ethanolamine tablets and will conduct clinical trials in the near future. Approval conclusion: According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, after review, the hytrapopa ethanolamine tablets (specification 2.5 mg) received on December 28, 2022 met the relevant requirements for drug registration, and it was agreed to launch combined cyclosporine (CsA) for the initial treatment of non-severe aplastic anemia (NSAA)

03-23 15:45

Hengrui Pharmaceutical: Subsidiary SHR8028 Eye Drop Drug Marketing License Application Accepted

03-20 16:58